Piramal Pharma Q4 FY26 Results Consolidated Loss Rs 8.82 Crore Impairment Charge Rs 176 Crore
- April 29, 2026
- Posted by: Harsh Piplani
- Category: News
Piramal Pharma Q4 FY26 Financial Highlights
Piramal Pharma reported a Q4 FY26 consolidated loss of Rs 8.82 crore, primarily due to a one-time impairment charge of Rs 176 crore on intangible assets under development. The impairment followed a reassessment of market conditions and updated commercial viability estimates for certain R and D assets. Excluding the impairment, underlying business operations showed improving trends.
| Metric | Q4 FY26 | Q4 FY25 | Change |
|---|---|---|---|
| Revenue / Total Income | approximately Rs 1,200 crore | Refer NSE filing | Grew (year-on-year growth) |
| Net Loss | Rs 8.82 crore | Refer NSE filing | Lower YoY |
| Full Year FY26 PAT | Refer annual filing | Refer filing | As reported |
| Dividend | Not declared | Refer filing | FY26 final |
Piramal Pharma Q4 FY26 Performance Analysis
Piramal Pharma’s CDMO (Contract Development and Manufacturing Organisation) business saw improving RFP momentum in H2 FY26, driven by meaningful recovery in US biopharma funding (up 75 percent YoY in H2 FY26) and increased M and A activity driving outsourcing demand.
The Consumer Healthcare business of Piramal Pharma showed growth momentum with Power Brands leading recovery. The company also completed the Kenalog acquisition and scaled inhalation anesthesia sales in ex-US markets, setting up FY27 growth.
Also Read: How to Invest Via Univest
Full Year FY26 Business Summary
FY26 was described by management as a transitional year for Piramal Pharma, shaped by external disruptions including inventory destocking, slower H1 CDMO order inflows, and softer inhalation anesthesia traction. The company exited FY26 on a stronger note with improving momentum.
Management Outlook and FY27 Priorities
Piramal Pharma’s FY27 outlook is constructive. Capex of USD 94 million invested in FY26 to scale sterile injectable and payload-linker capacities at Lexington and Riverview sites positions the CDMO business for meaningful revenue pick-up in FY27.
Conclusion
Piramal Pharma Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter with Net Loss of Rs 8.82 crore. The Pharmaceuticals and CDMO company’s results are an important input for investors tracking the earnings season. Investors should review the full exchange filing on NSE and BSE for complete audited financials before making any investment decisions.
This article is for informational and educational purposes only. It is not investment advice. Please consult a SEBI registered investment advisor before making any investment decisions. Past performance is not indicative of future results.
Frequently Asked Questions FAQs
What was Piramal Pharma Q4 FY26 PAT?
Piramal Pharma reported Q4 FY26 Net Loss of Rs 8.82 crore, lower year-on-year. The results were announced on April 28, 2026 via exchange filings on NSE and BSE.
What was Piramal Pharma revenue in Q4 FY26?
Piramal Pharma reported Q4 FY26 revenue of approximately Rs 1,200 crore (year-on-year growth). Investors should refer to the complete NSE and BSE exchange filing for the audited revenue breakdown.
Did Piramal Pharma declare a dividend for FY26?
As per available information, Piramal Pharma has not declared a dividend for FY26 in the Q4 results announcement. Refer to the official exchange filing for the latest update.
How did Piramal Pharma perform in FY26 overall?
FY26 was described by management as a transitional year for Piramal Pharma, shaped by external disruptions including inventory destocking, slower H1 CDMO order inflows, and softer inhalation anesthesia traction. The company exited FY26 on a stronger note with improving momentum…. Investors can track the complete annual performance metrics in the company’s FY26 annual report and exchange filings.
What is the outlook for Piramal Pharma in FY27?
Piramal Pharma’s FY27 outlook is constructive. Capex of USD 94 million invested in FY26 to scale sterile injectable and payload-linker capacities at Lexington and Riverview sites positions the CDMO business for meaningful revenue pick-up in FY27.. For real-time updates on the stock, investors should monitor regulatory filings and analyst commentary.
Where can I track Piramal Pharma stock and results?
Investors can track Piramal Pharma (NSE: PPLPHARMA) share price, financial results, and analyst data on NSE India, BSE India, and financial platforms. The Q4 FY26 results were filed on April 28, 2026.
What sector does Piramal Pharma operate in?
Piramal Pharma operates in the Pharmaceuticals and CDMO sector in India. The company is listed on both NSE and BSE. Investors should review the company’s business model, competitive positioning, and risk factors before making any investment decision.
Is Piramal Pharma a good investment after Q4 FY26 results?
Whether Piramal Pharma is a good investment depends on your individual financial goals, risk tolerance, and investment horizon. The Q4 FY26 results provide one data point about the company’s performance. Please consult a SEBI registered financial advisor before making any investment decision.
Recent Article
VRL Logistics Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Vraj Iron and Steel Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Voltas Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Voltamp Transformers Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Vodafone Idea Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
